DEXCOM INC

Dexcom’s recent slide sparks doubts about its growth: a sharp price dip, weak liquidity and rising competition threaten the company’s CGM dominance and investor confidence.

Dexcom stock drops 6.4% as stagnant growth, rising rates, and tech competition erode investor confidence—find out what the next steps could mean for its future.

Dexcom’s latest filing: a senior exec sold shares, yet the company’s strategy and share structure remain unchanged—stock dips modestly amid market volatility.

Dexcom shares near $85 as CGM tech steadies amid mixed sector moves; learn how market dynamics and diabetes demand shape its $32.5B valuation.